DNA nanotechnology for cell-free DNA marker for tumor detection: a comprehensive overview

• Published in: Nucleosides, nucleotides & nucleic acids nucleotides & nucleic acids, 2024-10, p.1-15
• Main Authors: Soliman, Sara Sami, Abd El-Samie, Fathi E, Abd El-Atty, Saied M, Badawy, Wael, Eshra, Abeer
• Format: Article
• Language: English
• ISSN: 1525-7770; 1532-2335; 1532-2335
• DOI: 10.1080/15257770.2024.2337853

Advancements in DNA nanotechnology have led to new exciting ways to detect cell-free tumor biomarkers, revolutionizing cancer diagnostics. This article comprehensively reviews recent developments in this field, discussing the significance of liquid biopsies and DNA nanomachines in early cancer detection. The accuracy of cancer diagnosis at its early stages is expected to be significantly improved by identifying biomarkers. Liquid biopsies, offering minimally-invasive testing, hold the potential for capturing tumor-specific components like circulating tumor cells, cell-free DNA, and exosomes. DNA nanomachines are advanced molecular devices that exploit the programmability of DNA sequences for the ultrasensitive and specific detection of these markers. DNA nanomachines, nanostructures made of DNA that can be designable and switchable nanostructures, have a wide range of advantages for detecting tumor biomarkers, including non-invasiveness, affordability, high sensitivity, and specificity. Scientists also work on dealing with challenges like low marker concentrations and interference, which are addressed through microfluidic integration, nanomaterial amplification, and indirect signal detection. Despite advances, multiplex detection remains a challenge. In conclusion, DNA nanomachines bear immense promise for cancer diagnostics, advocating personalized treatment and improving patient outcomes. Continued research could redefine how we find and treat tumors, leading to better patient outcomes.